Developing a Cell Therapy Treatment? Consider IHC Markers

Featured Story
SA-002186

Immunohistochemistry is a quantitative pathology tool that can optimize study design and execution by localizing cellular expression of proteins within the content of a tissue. IHC procedures are complicated, so it is crucial to partner with a provider who has extensive experience to prevent compromised data analysis and potential study repetition.

IHC markers provide visual evidence of the movement of therapeutic cells into tissues in an efficient way that optimizes biodistribution on a single cell basis. Biodistribution studies are a key study component for cell therapy programs during which the cell therapy product is evaluated for survival, integration in non-target tissues, and ability to endure in the animal model at the target site. The therapeutic cells can be detected using a variety of antibodies depending on the characterization of the cells. Examples of detection antibodies include STEM-121, anti-human CD45, anti-human mitochondria, and anti-human CD3. Additional staining for Ki67 can provide further evidence of whether the administered therapeutic cells are proliferative or not.

Explore our IHC portfolio